 - Participants must not have a history of life-threatening toxicity related to prior IO treatment eg, anti-CTLA-4 or anti-PD-1PD-L1 treatment or any other antibody or treatment specifically targeting T-cell co-stimulation or immune checkpoint pathways; i participants with toxicities that are unlikely to recur with standard countermeasures eg, hormone replacement treatment after adrenal crisis are eligible 